NCT07077512 2026-01-21
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
6 trialsNCT07326371 2026-01-08
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06365671 2026-01-06
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Ruijin Hospital
Phase 2 Recruiting
NCT06093841 2025-02-11
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Active not recruiting
NCT06479356 2024-08-21
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Recruiting
NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown